Edition:
India

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

81.54USD
20 Apr 2018
Change (% chg)

$-1.19 (-1.44%)
Prev Close
$82.73
Open
$82.51
Day's High
$82.68
Day's Low
$80.92
Volume
228,587
Avg. Vol
303,347
52-wk High
$95.82
52-wk Low
$63.69

Chart for

About

Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. It manufactures OTC healthcare... (more)

Overall

Beta: 0.70
Market Cap(Mil.): $12,381.50
Shares Outstanding(Mil.): 142.61
Dividend: 0.16
Yield (%): 0.74

Financials

  PRGO.N Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -20.55 -- --
ROI: -22.33 14.84 14.38
ROE: -38.96 16.34 16.07

BRIEF-Perrigo Says Terminated Existing Credit Agreements

* PERRIGO - EFFECTIVE MARCH 8, CO TERMINATED EXISTING CREDIT AGREEMENTS & REPLACED THEM WITH A NEW SENIOR UNSECURED REVOLVING AND TERM LOAN CREDIT AGREEMENT

10 Mar 2018

BRIEF-Perrigo - John Hendrickson's 2017 Total Compensation $8.3 Million Versus $5.8 Million In 2016

* PERRIGO COMPANY PLC CEO JOHN HENDRICKSON'S 2017 TOTAL COMPENSATION $8.3 MILLION VERSUS $5.8 MILLION IN 2016 - SEC FILING

10 Mar 2018

BRIEF-Perrigo CEO Buys 7,500 Shares Of Co's Ordinary Shares On March 5

* PERRIGO CEO UWE ROEHRHOFF REPORTS PURCHASE OF 7,500 SHARES OF CO'S ORDINARY SHARES ON MARCH 5 - SEC FILING Source text: (http://bit.ly/2Fpn04Z) Further company coverage:

08 Mar 2018

BRIEF-Perrigo Announces Final FDA Approval And Planned Launch For The Store Brand OTC Equivalent Of Mucinex DM Maximum Strength Extended Release Tablets

* PERRIGO ANNOUNCES FINAL FDA APPROVAL AND PLANNED LAUNCH FOR THE STORE BRAND OTC EQUIVALENT OF MUCINEX® DM MAXIMUM STRENGTH EXTENDED RELEASE TABLETS

07 Mar 2018

BRIEF-Perrigo Company Q4 GAAP Earnings Per Share $0.52

* REPORTS FOURTH QUARTER & CALENDAR YEAR 2017 FINANCIAL RESULTS

02 Mar 2018

BRIEF-Perrigo Company Reports Select Preliminary Unaudited 2017 Financial Results

* REPORTS SELECT PRELIMINARY UNAUDITED CALENDAR YEAR 2017 FINANCIAL RESULTS

27 Feb 2018

BRIEF-Perrigo Confirms Patent Challenge For Generic Version Of Finacea Foam, 15%

* PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF FINACEA® FOAM, 15%

20 Feb 2018

BRIEF-Perrigo Appoints Ronald Winowiecki As CFO

* PERRIGO APPOINTS RONALD L. WINOWIECKI AS CHIEF FINANCIAL OFFICER

20 Feb 2018

BRIEF-Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra Cream, 1%

* PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF SOOLANTRA® CREAM, 1% Source text for Eikon: Further company coverage:

30 Jan 2018

BRIEF-Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace Cream

* PERRIGO ANNOUNCES FINAL FDA APPROVAL OF A GENERIC VERSION OF ESTRACE CREAM

24 Jan 2018

Earnings vs. Estimates